Clinical trial
Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.
NCT00380302 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00380302 |
|---|---|
| Title | Activity of AVE1625 in Mild to Moderate Alzheimer's Patients. |
| Official title | A Double-Blind Placebo-Controlled Study of the Activity of AVE1625 at Doses of 10 mg and 40mg for 12 Weeks in Patients With Mild to Moderate Alzheimer's Disease |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | AVE1625 |
| Enrollment | 162 |
| Start date | Sep 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Sep 25, 2006 |
| Last update posted | Dec 19, 2008 |
| Countries | France, Italy, Netherlands, Sweden, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: